A Study of Cells in the Blood that may be Contributing to Allergic Inflammation in Asthmatics


About this study

The purpose of this study is to identify a new population of cells in the blood that may be contributing to allergic inflammation in atopic asthmatics.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Ages 18-75 years 

Normal Healthy Individuals

  • Healthy individuals with no history of asthma or allergy 
  • Normal spirometry   
  • Normal exhaled nitric oxide (eNO) test 
  • Blood eosinophils < 0.5 x 10 9 cells / L   
  • Negative skin prick test results or negative IgE serum tests to 10 common aeroallergens

Patients with Asthma with and without Nasal Polyps 

  • Asthma patients from the clinical practice of the Division of Allergic Diseases, Mayo Clinic Rochester 
  • The definition of asthma is based on the National Asthma Education and Prevention Program (NAEPP) 2007 Expert Panel Report  
  • Includes a physician’s determination that the subject’s history and physical examination are consistent with the diagnosis. 
  • Asthma patients have a history of variable airflow obstruction with at least 1 of the following:
    • Airway hyperreactivity (AHR)(PC20 methacholine ≤16 mg/ml) OR
    • A positive bronchodilator response (FEV1 change ≥12% following 2 puffs of albuterol (90 µg per puff) documented within the past 2 years. 

Exclusion Criteria

  • Received systemic glucocorticoids during the past 3 months
  • Previous (> 10 pack year smoking history) or current smokers
  • Lower or upper airway infection (eg. “cold”) in the last 4 weeks
  • Diagnosed with immunodeficiency, cystic fibrosis, or any other respiratory or general medical problem which in the investigator feels would preclude inclusion into the study e.g. infection, malignancy
  • Immunotherapy with any allergen
  • Pregnancy
  • Immunosuppressive medication

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Hirohito Kita, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer